LeMaitre Vascular stock hits 52-week low as analysts hold

Published on 10/01/2026 at 11:06 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Second-quarter revenue rose 9.60 percent to USD 70.38 million. LeMaitre Vascular stock has a USD 110.60 target versus its USD 78.22 low.

LMAT, US52567J1079, Illustration mit AI erstellt.

LeMaitre Vascular (US52567J1079) reached a new 52-week low of USD 78.22 on September 21, 2026, according to the dated market report. As MarketBeat reported on September 21, 2026, analyst sentiment was Hold, with an average price target of USD 110.60. The combination of a fresh yearly low and a target well above that level puts the earnings miss at the center of the stock narrative.

Quarterly growth missed expectations

LeMaitre Vascular generated USD 70.38 million in revenue during the second quarter of 2026, compared with a USD 71.47 million consensus estimate. MarketBeat reported that diluted earnings per share were USD 0.74 against a USD 0.81 forecast, while revenue still increased 9.60 percent from the second quarter of 2025. The result shows a clear split between operational growth and near-term execution against expectations.

The financial data for the second quarter also show net income attributable to common shareholders of USD 17.05 million and a net profit margin of 24.00 percent. Revenue growth therefore remained positive, but the earnings comparison was weaker than the consensus benchmark used by analysts.

Targets stay above the yearly low

The analyst picture is cautious rather than uniformly negative. Six analysts held a Hold view and three rated the stock Buy, producing the USD 110.60 average target cited by MarketBeat on September 20, 2026.

Target revisions have not all moved in the same direction. Wells Fargo lowered its price target from USD 104.00 to USD 94.00 and kept an Equal Weight rating in a research report dated August 5, 2026, while the broader consensus remained above the stock's USD 78.22 yearly low.

2026 guidance sets the test

LeMaitre's investor presentation dated August 4, 2026, sets 2026 full-year net sales guidance at USD 280.243 million, compared with adjusted 2025 sales of USD 249.602 million. The presentation also gives guidance for operating income of USD 77.759 million and diluted earnings per share of USD 2.91, versus adjusted 2025 diluted earnings per share of USD 2.38, implying 20.00 percent growth on that adjusted basis.

The same LeMaitre investor presentation identifies 163 sales representatives and 5,300 hospital accounts. It also states that more than 50.00 percent of 23,000 vascular surgeons worldwide use LeMaitre products, giving the guidance a measurable commercial base.

Market value remains compressed

LeMaitre Vascular had a market capitalization of USD 1.90 billion and a 52-week range of USD 78.22 to USD 118.01 as of September 30, 2026. The company is listed on Nasdaq under ticker LMAT and operates in healthcare medical instruments and supplies, according to Weiss Ratings.